Form 4: Apellis Pharmaceuticals Director Exercises Stock Options and Reports Beneficial Ownership Changes
SEC Form 4
Director A. Sinclair Dunlop reports exercising stock options and changes in beneficial ownership of Apellis Pharmaceuticals stock.
Summary
- On June 28, 2024, A. Sinclair Dunlop, a director of Apellis Pharmaceuticals, exercised stock options to acquire 900 shares of common stock at a price of $13.19 per share.
- Following this transaction, Dunlop directly owns 134,418 shares of Apellis common stock.
- Dunlop also indirectly owns 136,998 shares through Epidarex and 31,855 shares through MASA.
- The exercised stock option was granted on January 1, 2019, and was fully vested.
Sentiment
Score: 5
Explanation: This is a neutral filing related to stock option exercises, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 01/01/2019 | Stock option granted |
| 06/28/2024 | Transaction Date: Stock options exercised |
| 07/01/2024 | Date of signature for the report |
| 12/31/2028 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.